JP2016514091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514091A5 JP2016514091A5 JP2015557148A JP2015557148A JP2016514091A5 JP 2016514091 A5 JP2016514091 A5 JP 2016514091A5 JP 2015557148 A JP2015557148 A JP 2015557148A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2016514091 A5 JP2016514091 A5 JP 2016514091A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- antibody
- ttr
- item
- native
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims description 198
- 108010071690 Prealbumin Proteins 0.000 claims description 85
- 102000009190 Transthyretin Human genes 0.000 claims description 85
- 206010002022 amyloidosis Diseases 0.000 claims description 27
- 102200150628 rs151220873 Human genes 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 10
- 102220040362 rs141591400 Human genes 0.000 claims description 6
- 238000000159 protein binding assay Methods 0.000 claims description 4
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 3
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 3
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims description 3
- 102220471946 Axin interactor, dorsalization-associated protein_H56R_mutation Human genes 0.000 claims description 2
- 102220600742 Calmodulin-binding transcription activator 1_G53A_mutation Human genes 0.000 claims description 2
- 102220544656 Coagulation factor X_E54G_mutation Human genes 0.000 claims description 2
- 102220520746 Cystatin-C_A25S_mutation Human genes 0.000 claims description 2
- 102220465994 Dihydrofolate reductase 2, mitochondrial_I68M_mutation Human genes 0.000 claims description 2
- 102220465992 Dihydrofolate reductase 2, mitochondrial_Y69H_mutation Human genes 0.000 claims description 2
- 102220476001 Ectodysplasin-A_L55R_mutation Human genes 0.000 claims description 2
- 102220566386 Forkhead box protein L2_I84N_mutation Human genes 0.000 claims description 2
- 102220566385 Forkhead box protein L2_I84S_mutation Human genes 0.000 claims description 2
- 102220616501 Gamma-crystallin D_A36P_mutation Human genes 0.000 claims description 2
- 102220539815 HLA class II histocompatibility antigen, DQ beta 1 chain_Y69I_mutation Human genes 0.000 claims description 2
- 102220585092 Histone H3.Y_A97S_mutation Human genes 0.000 claims description 2
- 102220505281 NADH-ubiquinone oxidoreductase chain 5_I84T_mutation Human genes 0.000 claims description 2
- 102220505300 NADH-ubiquinone oxidoreductase chain 5_V122I_mutation Human genes 0.000 claims description 2
- 102220505315 NADH-ubiquinone oxidoreductase chain 5_V20I_mutation Human genes 0.000 claims description 2
- 102220475913 Oligophrenin-1_E89K_mutation Human genes 0.000 claims description 2
- 102220511395 Proteasome subunit beta type-10_K35T_mutation Human genes 0.000 claims description 2
- 102220467909 Protein Dok-7_V32A_mutation Human genes 0.000 claims description 2
- 102220645376 Sodium- and chloride-dependent betaine transporter_C10R_mutation Human genes 0.000 claims description 2
- 102220494820 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial_F33V_mutation Human genes 0.000 claims description 2
- 102220536557 Transcription factor NF-E4_A45D_mutation Human genes 0.000 claims description 2
- 102220579299 Transthyretin_D38E_mutation Human genes 0.000 claims description 2
- 102220579482 Transthyretin_G67E_mutation Human genes 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 102220357373 c.265G>C Human genes 0.000 claims description 2
- 102220414639 c.325G>T Human genes 0.000 claims description 2
- 102220353134 c.68G>A Human genes 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 102220284214 rs1000821034 Human genes 0.000 claims description 2
- 102200070532 rs104894304 Human genes 0.000 claims description 2
- 102200160559 rs104894505 Human genes 0.000 claims description 2
- 102220004692 rs104894664 Human genes 0.000 claims description 2
- 102200115856 rs104894665 Human genes 0.000 claims description 2
- 102220223852 rs1060502978 Human genes 0.000 claims description 2
- 102220224292 rs1060503516 Human genes 0.000 claims description 2
- 102200061512 rs1064039 Human genes 0.000 claims description 2
- 102200142586 rs11125895 Human genes 0.000 claims description 2
- 102220074162 rs113134544 Human genes 0.000 claims description 2
- 102200114145 rs121434245 Human genes 0.000 claims description 2
- 102200009417 rs121908117 Human genes 0.000 claims description 2
- 102220198133 rs121913385 Human genes 0.000 claims description 2
- 102220054792 rs138065384 Human genes 0.000 claims description 2
- 102220249923 rs1427260162 Human genes 0.000 claims description 2
- 102220142452 rs147257284 Human genes 0.000 claims description 2
- 102220294668 rs1554558878 Human genes 0.000 claims description 2
- 102220242123 rs1556105849 Human genes 0.000 claims description 2
- 102200049725 rs182983506 Human genes 0.000 claims description 2
- 102220039279 rs199473356 Human genes 0.000 claims description 2
- 102220035386 rs200930463 Human genes 0.000 claims description 2
- 102220294624 rs201073751 Human genes 0.000 claims description 2
- 102200112216 rs2273285 Human genes 0.000 claims description 2
- 102200111232 rs28931605 Human genes 0.000 claims description 2
- 102200118257 rs33935983 Human genes 0.000 claims description 2
- 102220005419 rs33976776 Human genes 0.000 claims description 2
- 102220005148 rs34743882 Human genes 0.000 claims description 2
- 102220005545 rs34769782 Human genes 0.000 claims description 2
- 102200082806 rs35303218 Human genes 0.000 claims description 2
- 102200124261 rs374259530 Human genes 0.000 claims description 2
- 102220227599 rs530501230 Human genes 0.000 claims description 2
- 102220162602 rs549769200 Human genes 0.000 claims description 2
- 102200055608 rs61732504 Human genes 0.000 claims description 2
- 102220033838 rs61753984 Human genes 0.000 claims description 2
- 102220056953 rs730880945 Human genes 0.000 claims description 2
- 102220178356 rs769686237 Human genes 0.000 claims description 2
- 102220062179 rs786201468 Human genes 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 description 27
- 230000002744 anti-aggregatory effect Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical group C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical group O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 2
- 229960001353 tafamidis Drugs 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762750P | 2013-02-08 | 2013-02-08 | |
| US61/762,750 | 2013-02-08 | ||
| US201361863818P | 2013-08-08 | 2013-08-08 | |
| US61/863,818 | 2013-08-08 | ||
| PCT/US2014/015421 WO2014124334A2 (en) | 2013-02-08 | 2014-02-07 | Transthyretin antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514091A JP2016514091A (ja) | 2016-05-19 |
| JP2016514091A5 true JP2016514091A5 (https=) | 2017-03-02 |
Family
ID=51300272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557148A Pending JP2016514091A (ja) | 2013-02-08 | 2014-02-07 | トランスサイレチン抗体およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9790269B2 (https=) |
| EP (1) | EP2953970A4 (https=) |
| JP (1) | JP2016514091A (https=) |
| WO (1) | WO2014124334A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3022225B1 (en) * | 2013-07-19 | 2021-09-29 | Board Of Regents Of the University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| US10344080B2 (en) | 2013-12-20 | 2019-07-09 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor |
| EP3101131B1 (en) * | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
| EP3981874A1 (en) | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI786505B (zh) * | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI769570B (zh) * | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) * | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| WO2018007923A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3468272B1 (en) * | 2016-09-10 | 2025-12-17 | LG Electronics Inc. | Method for allocating v2x resource pool to subframe remaining after excluding specific subframe in wireless communication system, and terminal using same |
| BR112019005378A2 (pt) | 2016-09-19 | 2019-08-27 | The Trustees Of The University Of Pennsylvania | molécula de ácido nucleico, composição, e, métodos para prevenir ou tratar uma doença e para induzir uma resposta imune |
| CU24731B1 (es) | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| CN111757730A (zh) * | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| CU20200042A7 (es) | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| WO2019241497A1 (en) * | 2018-06-13 | 2019-12-19 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against zika virus |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| JP7360142B2 (ja) * | 2019-05-21 | 2023-10-12 | 国立大学法人 熊本大学 | アミロイドーシス治療薬の新規スクリーニング方法 |
| EP3976017A4 (en) * | 2019-05-31 | 2023-06-14 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE |
| EP3988122A4 (en) * | 2019-12-17 | 2023-01-18 | Yizhou (Shanghai) Biological Medicine Co, Ltd. | USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS |
| CN215606058U (zh) | 2020-06-03 | 2022-01-25 | 巴德阿克塞斯系统股份有限公司 | 配置用于与骨内进入系统一起使用的闭塞器组件 |
| CN114098918B (zh) | 2020-08-25 | 2025-12-12 | 巴德阿克塞斯系统股份有限公司 | 成角度的骨内进入系统 |
| EP4203821B1 (en) | 2020-09-01 | 2025-10-29 | Bard Access Systems, Inc. | Retractable intraosseous access system |
| CN215839325U (zh) * | 2020-09-09 | 2022-02-18 | 巴德阿克塞斯系统股份有限公司 | 用于骨内进入系统的抽吸设备 |
| JP7504304B2 (ja) | 2021-01-19 | 2024-06-21 | エリモス・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸（ｎｄｇａ）誘導体 |
| CN217960227U (zh) | 2021-02-08 | 2022-12-06 | 巴德阿克塞斯系统股份有限公司 | 骨内进入系统 |
| CN117916599A (zh) | 2021-09-07 | 2024-04-19 | 美国西门子医学诊断股份有限公司 | 生物标记物组合物及其使用方法 |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| EP4296279A1 (en) * | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
| EP4630812A1 (en) | 2022-12-05 | 2025-10-15 | Neurimmune AG | Cyclic compounds and their use in assays for detecting antibodies |
| CN116396392B (zh) * | 2023-01-17 | 2023-10-27 | 珠海重链生物科技有限公司 | 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用 |
| SE2350342A1 (en) * | 2023-03-27 | 2024-09-28 | Anders Olofsson | Composition for use in prevention and/or treatment of human transthyretin amyloidosis |
| WO2024240562A1 (en) * | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| CN121646476A (zh) | 2023-06-07 | 2026-03-10 | 神经免疫有限公司 | 用于治疗淀粉样变性的疫苗 |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5156965A (en) | 1983-11-29 | 1992-10-20 | Igen, Inc. | Catalytic antibodies |
| CH668554A5 (de) | 1984-04-09 | 1989-01-13 | Sandoz Ag | Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung. |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| DE3682257D1 (de) | 1985-11-22 | 1991-12-05 | Takeda Chemical Industries Ltd | Liposomzusammensetzung. |
| JP2666345B2 (ja) | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5658753A (en) | 1989-04-25 | 1997-08-19 | Paul; Sudhir | Catalytic antibody components |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| EP1285967A3 (en) | 1990-09-21 | 2005-03-02 | Chiron Corporation | Human retroviral packaging cell line |
| DE69131908T3 (de) | 1991-02-19 | 2008-04-03 | Oxford Biomedica (Uk) Ltd. | Viruspartikel mit veraendertem wirtspektrum |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| AU3972893A (en) | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| EP0728202A4 (en) | 1993-11-12 | 1997-04-23 | Univ Case Western Reserve | EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY |
| US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997026919A2 (en) | 1996-01-24 | 1997-07-31 | Warner-Lambert Company | Method of imaging amyloid deposits |
| US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
| US6472436B1 (en) | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| US7311893B2 (en) | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
| WO2002028441A2 (en) | 2000-10-04 | 2002-04-11 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
| WO2002085903A2 (en) | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| ATE405840T1 (de) | 2002-12-19 | 2008-09-15 | Scripps Research Inst | Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung |
| ES2273202T3 (es) | 2003-01-07 | 2007-05-01 | Symphogen A/S | Procedimiento para producir proteinas policlonales recombinantes. |
| US20060035946A1 (en) | 2003-01-22 | 2006-02-16 | The General Hospital Corporation | Amyloid-binding, metal-chelating agents |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| KR20070032700A (ko) | 2004-05-20 | 2007-03-22 | 폴드알엑스 파마슈티칼스, 인크. | 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법 |
| ES2332524T3 (es) | 2004-07-20 | 2010-02-08 | Symphogen A/S | Un procedimiento para la caracterizacion de una linea celular policlonal. |
| CA2638753A1 (en) | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| US20070111258A1 (en) | 2005-06-22 | 2007-05-17 | Kaufman Randal J | Compositions and methods for modulating the acute phase response |
| EP1921916A2 (en) | 2005-08-11 | 2008-05-21 | The Scripps Research Institute | Genistein inhibition of transthyretin amyloidosis |
| US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| CA2668640A1 (en) * | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
| WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| HRP20100640T1 (hr) | 2007-05-25 | 2010-12-31 | Symphogen A/S | Postupak proizvodnje rekombinantnog poliklonskog proteina |
| US20090123373A1 (en) | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
| CA2702322A1 (en) | 2007-11-22 | 2009-05-28 | Symphogen A/S | A method for characterization of a recombinant polyclonal protein |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| AU2009301580B2 (en) * | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| US8283460B2 (en) | 2008-10-15 | 2012-10-09 | Somagenics, Inc. | Short hairpin RNAs for inhibition of gene expression |
| EA036772B1 (ru) | 2008-10-20 | 2020-12-18 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии транстиретина |
| CA2749163A1 (en) | 2009-01-14 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
| JP2010195710A (ja) * | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
| WO2011100396A2 (en) * | 2010-02-10 | 2011-08-18 | Trustees Of Boston University | Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy |
| EP3329924B1 (en) | 2010-03-29 | 2021-05-05 | Alnylam Pharmaceuticals, Inc. | Dsrna therapy for transthyretin (ttr) related ocular amyloidosis |
| WO2011140333A1 (en) | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
-
2014
- 2014-02-07 EP EP14749029.6A patent/EP2953970A4/en not_active Withdrawn
- 2014-02-07 JP JP2015557148A patent/JP2016514091A/ja active Pending
- 2014-02-07 US US14/760,194 patent/US9790269B2/en active Active
- 2014-02-07 WO PCT/US2014/015421 patent/WO2014124334A2/en not_active Ceased
-
2017
- 2017-09-26 US US15/716,154 patent/US20180022797A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514091A5 (https=) | ||
| Caine et al. | Borrelia burgdorferi outer surface protein C (O sp C) binds complement component C 4b and confers bloodstream survival | |
| Sellers et al. | The hidden burden of influenza: a review of the extra‐pulmonary complications of influenza infection | |
| Lannfelt et al. | Perspectives on future Alzheimer therapies: amyloid-β protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer’s disease | |
| Imbimbo et al. | Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease | |
| Bustamante et al. | A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants | |
| Pauly et al. | A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples | |
| DeMattos et al. | A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice | |
| Kontsekova et al. | Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease | |
| US9849165B2 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| JP6263473B2 (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| AU2018392605B2 (en) | Methods for developing pharmaceuticals for treating neurodegenerative conditions | |
| Efthymiou et al. | Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis:(ir) Relevance to disease pathogenesis | |
| Vermeire et al. | Value of drug level testing and antibody assays in optimising biological therapy | |
| Gresa-Arribas et al. | Diagnosis and significance of antibody titers in anti-NMDA receptor encephalitis, a retrospective study | |
| Vaishnav et al. | Aquaporin 4 molecular mimicry and implications for neuromyelitis optica | |
| JP7732015B2 (ja) | アルファ－シヌクレインアッセイ | |
| EP3837286A1 (en) | Antibodies to human znt8 | |
| Filli et al. | Predicting responsiveness to fampridine in gait‐impaired patients with multiple sclerosis | |
| JP7258762B2 (ja) | 新規アミロイドベータオリゴマー特異的結合分子 | |
| Rasheed | Hydroxyl radical damaged immunoglobulin G in patients with rheumatoid arthritis: biochemical and immunological studies | |
| Chatzimichail et al. | Ranibizumab biosimilars in treating retinal disorders: a cost-effective revolution? | |
| Trieu et al. | Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens | |
| Douma et al. | Autoimmune encephalitis in Tunisia: report of a pediatric cohort | |
| EP2778173A1 (en) | Antibody directed against anthrax toxins and its uses |